Inactive Instrument

Analyst Reco. Immutep Ltd Australian S.E.

Equities

Baird Initiates Immutep With Outperform Rating, $7 Price Target	23-08-03	MT
Maxim Group Adjusts Price Target on Immutep to $10 From $8, Keeps Buy Rating	23-05-18	MT
Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers	22-06-03	CI
AIPAC final data as expected: Phase III supported with maintaining a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	21-11-11	PU
O/W: IMMune to failure - Initiating coverage with a Buy Rating (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)	21-11-03	PU
Immutep : Ladenburg Thalman - New Age Immune Regulator; Initiate with a Buy Rating and $8.30 Price Target	21-08-03	PU
IMMUTEP : Ladenburg Thalmann Starts Immutep at Buy With $8.30 Price Target	21-08-03	MT
Immutep : Maxim Group - Unlocking the Synergistic Benefits of Efti (LAG-3), the Next Checkpoint - Transferring Coverage with a Buy Rating and $8 PT	21-07-16	PU

No results for this search